

Clinical Trial Protocol

Iranian Registry of Clinical Trials

08 Jul 2026

The comparison of the effect of magnesium oxide and sodium valproate in migraine prophylaxis: A prospective double blind randomized clinical trial

Protocol summary

Summary

This study is clinical trial, double blind and cross over. Patients divided to two groups randomly. Participants were randomized in a 1:1 ratio to receive either valproate Na 400 Mg or magnesium oxide 500 mg twice a day for two months. After 4 weeks of washout, participants crossed over to receive the alternative intervention for 2 months. The intensity of migraine headache is evaluated with IV grading and VAS 1-10 and we used questionnaire Migraine Disability Assessment Test that is a test used by doctors to determine how severely migraines affect a patient's life. Inclusion criteria: migraine headache on based criteria HIS; age between 15-65 years old; migraine headache from 6 month ago, headache frequency: more than twice a month with moderate or severe intensity; not used valproate Na and MG within the past 30 days. Exclusion criteria: pregnancy, breastfeeding, renal and hepatic failure, non migraine headache, abused smoke and opium.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201501171666N2**

Registration date: **2015-03-05, 1393/12/14**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2015-03-05, 1393/12/14

Registrant information

Name

Narges Karimi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 11 3311 6275

Email address

n.karimi@mazums.ac.ir

Recruitment status

Recruitment complete

Funding source

Mazandaran University of Medical Sciences

Expected recruitment start date

2015-03-01, 1393/12/10

Expected recruitment end date

2017-02-19, 1395/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The comparison of the effect of magnesium oxide and sodium valproate in migraine prophylaxis: A prospective double blind randomized clinical trial

Public title

The comparison of the effect of magnesium oxide and sodium valproate in migraine prophylaxis:

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: migraine headache on based criteria IHS; age between 15-65 years old; migraine headache from 6 month ago; headache frequency: more than twice a month with moderate or sever intensity; not used valproate Na and MG within the past 30 days. Exclusion

criteria: pregnancy; breastfeeding; renal and hepatic failure; non migraine headache; smoking and opium and substance abuse.

Age

From **15 years** old to **65 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **80**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Not used

Assignment

Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Mazandaran University of Medical Sceinces

Street address

Mazandaran University of Medical Sceinces, Joibar
three way

City

Sari

Postal code

Approval date

2014-11-19, 1393/08/28

Ethics committee reference number

791

Health conditions studied

1

Description of health condition studied

Migrain headache

ICD-10 code

G43

ICD-10 code description

Migraine

Primary outcomes

1

Description

Headache intensity

Timepoint

2 months after used drug

Method of measurement

Questionnaire MIDAS and VAS 1-10

2

Description

Headache frequency

Timepoint

2 months after used drug

Method of measurement

Questionnaire MIDAS

3

Description

Headache duration

Timepoint

2 months after used drug

Method of measurement

Questionnaire MIDAS

Secondary outcomes

1

Description

Headache symptom

Timepoint

2 month after use drug

Method of measurement

Questionnair

Intervention groups

1

Description

Control group: Tab. Valproat Na 200mg BD for 2 month

Category

Treatment - Drugs

2

Description

intervention: tab magnesium oxide 250 mg BD for 2
month

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Tooba clinic

Full name of responsible person

Narges Karimi

Street address**City**

Sari

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Mazandaran University of Medical Sciences

Full name of responsible person

Ahmad Ali Enayati

Street address

Moalem square

City

Sari

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Mazandaran University of Medical Sciences

Proportion provided by this source

100

Public or private sector*empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***Person responsible for general inquiries****Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

Full name of responsible person

Narges karimi

Position

Neurologist

Other areas of specialty/work**Street address**

Bou Ali Sina hospital

City

Sari

Postal code**Phone**

+98 11 3334 3018

Fax**Email**

drkarimi_236@yahoo.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

Full name of responsible person

Narges karimi

Position

Neurologist

Other areas of specialty/work**Street address**

Bou Ali Sina hospital

City

Sari

Postal code**Phone**

+98 11 3334 3018

Fax**Email**

drkarimi_236@yahoo.com

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

Full name of responsible person

Narges Karimi

Position

Neurologist

Other areas of specialty/work**Street address****City**

Sari

Postal code**Phone**

+98 33343018

Fax**Email****Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)***empty***Study Protocol***empty***Statistical Analysis Plan***empty***Informed Consent Form***empty***Clinical Study Report***empty***Analytic Code***empty***Data Dictionary***empty*